Strategic Alliances

FibroGen welcomes the opportunity to build alliances that complement the Company's strengths. We seek partners with research, development, and marketing capabilities and other resources that strengthen our ability to advance our own or jointly developed product candidates.

In 2006, FibroGen completed an exclusive licensing agreement with Astellas Pharma Inc. that provides Astellas development and marketing rights to certain FibroGen HIF prolyl hydroxylase inhibitors for the treatment of anemia in Europe, Commonwealth of Independent States (CIS), Middle East, and South Africa. These inhibitors include FG-2216 and FG-4592. FibroGen retains rights in the rest of the world except in Japan. The Japan rights were licensed previously to Yamanouchi (now Astellas) in 2004.
In 1998, FibroGen and Medarex, Inc. entered into an antibody development agreement for potential anti-fibrotic therapies.

In 2006, FibroGen completed an exclusive licensing agreement with Astellas Pharma Inc. that provides Astellas development and marketing rights to certain FibroGen HIF prolyl hydroxylase inhibitors for the treatment of anemia in Europe, Commonwealth of Independent States (CIS), Middle East, and South Africa. These inhibitors include FG-2216 and FG-4592. FibroGen retains rights in the rest of the world except in Japan. The Japan rights were licensed previously to Yamanouchi (now Astellas) in 2004.

In 1998, FibroGen and Medarex, Inc. entered into an antibody development agreement for potential anti-fibrotic therapies.